Clinical trials are evolving in response to growing expectations around diversity, accessibility and patient-centricity.
Improving diversity in clinical trials can help generate more representative evidence and strengthen confidence in treatment performance across different patient groups. However, building study populations that reflect real-world patients remains a significant challenge.
In this article, Julie Massicotte, Senior Director, Regulatory Affairs at Indero, explores how sponsors can address these issues earlier in the trial life cycle through more inclusive protocol design, patient-focused recruitment strategies and stronger statistical planning.
Check out the rest of the feature here
